Tasquinimod

DB05861InvestigationalSmall molecule

The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.

Primary indication: Investigated for use/treatment in prostate cancer.Curator reviewed
Formula / weight: C₂₀H₁₇F₃N₂O₄ · 406.361 g/mol (avg)
Also known as: TASQ
Code names: ABR-215050

Resolves to

Compound

UNII756U07KN1RCAS254964-60-8ChEMBLCHEMBL2107784PubChem54682876

Structure

InChIKeyONDYALNGTUAJDX-UHFFFAOYSA-NSMILESCOC1=CC=CC2=C1C(O)=C(C(=O)N(C)C1=CC=C(C=C1)C(F)(F)F)C(=O)N2C

Targets

P06702S100A9

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tasquinimod, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account